Peptide Agonist
|
1 |
CST-14 |
MRGPRX2-dependent MC activation, degranulation and cytokine release
Increased Ca2+ mobilization
Involvement of store-operated Ca2+ entry via stim1
|
[72,75,104] |
2 |
Substance P |
Presence of MRGPRs in primary sensory neurons and on nerve endings of dorsal root ganglion
MRGPRX2-dependent activation of human skin-derived cultured MCs
MRGPRX2-dependent itch response
|
[46,67,70] |
3 |
Somatostatin |
|
[45,73] |
4 |
PACAP |
|
[45] |
5 |
VIP |
|
[45] |
6 |
LL-37 |
MRGPRX2-dependent LL-37 induces MC degranulation, chemokine generation, and chemotaxis
Increased Ca2+ mobilization
|
[50,103] |
7 |
β-defensins |
|
[103] |
8 |
Indolicidin |
|
[45] |
9 |
PAMP 20 |
|
[75,105] |
10 |
Mastoparan |
|
[72,91] |
11 |
Human eosinophil granules |
MRGPRX2-dependent activation of human MCs
Identified major basic protein-1 (MBP-1) and major basic protein-2 (MBP-2), eosinophil peroxidase (EPO) and eosinophil cationic protein (ECP) as MRGPRX2 agonists
|
[45,46,106] |
12 |
Proteases |
|
[107,108] |
13 |
AG-30/5C |
|
[95] |
14 |
AMP-IBP5 |
Identified AMP-IBP5 as MRGPRX2 agonist
Role in wound healing through MCs–MRGPRX2
AMP-IBP5 shown Ca2+ flux followed by MC degranulation and release PGDs, and cytokines/chemokines.
|
[48] |
15 |
GnRHR agonist and antagonist |
|
[72] |
Non-peptide agonist
|
1 |
Compound 48/80 |
MRGPRX2-dependent MC activation of different population of MCs
Increased Ca2+ mobilization, and cytokine release
|
[45,72,109] |
2 |
Fluoroquinolone antibiotics (ciprofloxacin) |
MRGPRX2-dependent hypersensitivity reaction by topical fluoroquinolone ophthalmic preparation
Concentration-dependent MC degranulation, and MRGPRX2-dependent Ca2+ release by ciprofloxacin
Dose dependent MC degranulation, Ca2+ release and increased vascular permeability
|
[72,110,111] |
3 |
NMBAs (rocuronium, mivacurium, and atracurium) |
Rocuronium-induced non-IgE-mediated allergic reaction clinically
Concentration-dependent MCs–MRGPRX2/MRGPRB2 by rocuronium
MC Ca2+ mobilization and degranulation concentration-dependent activation of MRGPRX2, MC degranulation, histamine and inflammatory cytokine release by mivacurium
Increased paw extravasation and decreased body temperature by mivacurium
|
[72,85,112] |
4 |
Opioids (morphine, pethidine chloride, dextrorphan, levorphanol) |
MRGPRX2-mediated MC activation and intrathecal mass formation.
Concentration-dependent MRGPRX2 activation and MC activity of morphine
Dextro-enantiomers and N-methyl scaffolds of opioids and endogenous opioid ligands activates MCs via MRGPRX2
Increased Ca2+ mobilization and MC degranulation activity
Concentration-dependent human MC degranulation and inflammatory cytokine release by pethidine hydrocholoride
|
[87,113,114] |
5 |
Antidepressant drugs (clomipramine paroxetine and desipramine |
Concentration-dependent activation of MRGPRX2/MRGPRB2 and MC activation
Induced scratch behavior in mice
Clomipramine showed wheal-and-flare reaction on intradermal injection and activated human skin MCs
|
[115] |
6 |
Others (Icatibant, iopamidol, vancomycin, baicalein, and sinomemnin) |
MRGPRX2/MRGPRB2 activation
MC degranulation and Ca2+ mobilization
Induced tissue extravasation and cytokine release
|
[72,92,95,116] |